(Q46515640)

22 December 2017

title

Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma (English)

1 reference

22 December 2017

0 references

1 reference

8

Patrick Hwu

1 reference

22 December 2017

author name string

Agop Y Bedikian

1

1 reference

22 December 2017

Marcella M Johnson

2

1 reference

22 December 2017

Carla L Warneke

3

1 reference

22 December 2017

Nicholas E Papadopoulos

4

1 reference

22 December 2017

Kevin Kim

5

1 reference

22 December 2017

Wen-Jen Hwu

6

1 reference

22 December 2017

Susan McIntyre

7

1 reference

22 December 2017

publication date

1 July 2008

1 reference

22 December 2017

published in

Cancer Investigation

1 reference

22 December 2017

volume

26

1 reference

22 December 2017

page(s)

624-633

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Prognostic factors in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802027073

10.1080/07357900802027073

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

18584354

1 reference

22 December 2017